Helena Yu, MD
Internal Medicine · New York, NYNPI 1871791665
Payments from drug & device makers
Across 965 payments — averaging $52,750 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$33.9M
- Pfizer$10.1M
- Daiichi Sankyo Inc.$4.6M
- Janssen Research & Development, LLC$1M
- Novartis$628K
- Blueprint Medicines Corporation$195K
- plus $524K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $33,872,325 |
| Pfizer | 58 | $10,068,026 |
| Daiichi Sankyo Inc. | 661 | $4,586,401 |
| Janssen Research & Development, LLC | 23 | $1,028,797 |
| Novartis | 9 | $628,444 |
| Blueprint Medicines Corporation | 17 | $195,097 |
| Clovis Oncology, Inc. | 3 | $134,509 |
| Beone Medicines USA, Inc. | 7 | $122,008 |
| Eli Lilly | 5 | $96,591 |
| Astrazeneca UK Limited | 21 | $54,027 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $26,892 |
| Johnson & Johnson(2 entities) | 16 | $18,174 |
| Janssen Scientific Affairs, LLC | 14 | $15,848 |
| Janssen Global Services, LLC | 11 | $11,060 |
| Merck | 8 | $7,687 |
| Gilead | 2 | $7,150 |
| AbbVie | 2 | $5,738 |
| Novocure Inc. | 2 | $5,099 |
| E.r. Squibb & Sons, L.L.C. | 4 | $4,371 |
| Ipsen Bioscience Inc. | 1 | $4,350 |
| Taiho Oncology, Inc. | 2 | $2,196 |
| Bayer | 1 | $2,100 |
| Rigel Pharmaceuticals, Inc. | 3 | $1,870 |
| Array Biopharma Inc | 2 | $1,541 |
| Orion Corporation | 2 | $1,511 |
| Puma Biotechnology, Inc. | 1 | $908 |
| Boehringer Ingelheim | 1 | $650 |
How this compares
$50,903,366 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in New York
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
- Claire FriedmanNew York$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.